What do systematic reviews say?

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy vs placebo

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

The review found no eligible studies for this question.

• Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Ultrasound‐guided foam sclerotherapy vs conventional surgery

Ultrasound‐guided foam sclerotherapy showed no clear difference in recurrence of reflux at 1 year compared with conventional surgery (low certainty).

• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  OR 1.19 [0.29, 4.92]
  1 study · 31 participants
  Low

Ultrasound‐guided foam sclerotherapy vs conventional surgery

• Endovenous ablation therapy (laser or radiofrequency) or foam sclerotherapy versus conventional surgical repair for… 2016 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 31 participants
  GRADE not reported

Ultrasound‐guided foam sclerotherapy vs SFJ ligation and stripping (HL/S)

Ultrasound‐guided foam sclerotherapy (UGFS) showed no clear difference in recurrence (< 5 years) compared with SFJ ligation and stripping (HL/S) (low certainty).

• Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
  OR 1.81 [0.87, 3.77]
  3 studies · 822 participants
  Low

Ultrasound‐guided foam sclerotherapy vs SFJ ligation and stripping (HL/S)

Ultrasound‐guided foam sclerotherapy (UGFS) showed no clear difference in long‐term recurrence (≥ 5 years) compared with SFJ ligation and stripping (HL/S) (low certainty).

• Interventions for great saphenous vein incompetence 2021 · Cochrane Headline outcomes only
  OR 1.24 [0.57, 2.71]
  3 studies · 639 participants
  Low